September 22, 2020 10:49 AM EDTUpdated 11:29 AM

News briefing: Tiny Vaccinex's drug flops in PhII Huntington's trial, stock craters; Siolta nabs $30M Series B to develop microbiome drug

Siolta Therapeutics, a microbiome company targeting allergic diseases, raked in a $30 million Series B to develop its lead candidate …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News brief­ing: Tiny Vac­cinex's drug flops in PhII Hunt­ing­ton's tri­al, stock craters; Siol­ta nabs $30M Se­ries B to de­vel­op mi­cro­bio­me drug